AU
CA
NZ
UK
US
IND
Kalkine has a fully transformed New Avatar.
Last update at 2026-03-10T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
1 Russell 2000 Stock with Solid Fundamentals and 2 to Steer Clear Of
Fri 23 May 25, 04:31 AMCONMED Corporation Appoints LaVerne Council as Chair of the Board of Directors
Wed 21 May 25, 11:03 AMFiring on All Cylinders: CONMED (NYSE:CNMD) Q1 Earnings Lead the Way
Tue 20 May 25, 03:35 AMHere's Why Conmed (CNMD) is a Strong Value Stock
Mon 19 May 25, 01:40 PMCNMD Q1 Earnings Call: Supply Chain Progress, Growth Drivers, and Tariff Mitigation in Focus
Wed 14 May 25, 03:37 PMSTERIS (STE) Q1 Earnings: What To Expect
Tue 13 May 25, 07:01 AMImpressive Earnings May Not Tell The Whole Story For CONMED (NYSE:CNMD)
Thu 08 May 25, 10:26 AMSolventum Earnings: What To Look For From SOLV
Wed 07 May 25, 07:05 AM1 Safe-and-Steady Stock to Consider Right Now and 2 to Be Wary Of
Mon 05 May 25, 04:41 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -70.86200M | 73.11M | 1.60M | 31.23M | 50.65M |
| Minority interest | - | - | - | - | - |
| Net income | -80.58200M | 62.54M | 9.52M | 28.62M | 40.85M |
| Selling general administrative | 454.04M | 414.75M | 373.82M | 400.14M | 355.62M |
| Selling and marketing expenses | - | - | 373.82M | - | - |
| Gross profit | 571.25M | 568.04M | 460.30M | 524.72M | 469.11M |
| Reconciled depreciation | 69.52M | 70.74M | 72.62M | 72.32M | 61.80M |
| Ebit | 70.05M | 37.85M | -26.97000M | 1.60M | 9.50M |
| Ebitda | -41.95700M | 108.59M | 45.66M | 73.93M | 71.31M |
| Depreciation and amortization | -112.01100M | 70.74M | 72.62M | 72.32M | 61.80M |
| Non operating income net other | -112.01100M | -1.12700M | -0.35500M | -5.18800M | - |
| Operating income | 70.05M | 37.85M | -26.97000M | 1.60M | 71.31M |
| Other operating expenses | 975.42M | 900.92M | 816.45M | 875.98M | 788.33M |
| Interest expense | 28.91M | 35.48M | 44.05M | 42.70M | 20.65M |
| Tax provision | 9.72M | 10.56M | -7.91400M | 2.60M | 9.80M |
| Interest income | - | - | - | 42.70M | 20.65M |
| Net interest income | -28.90500M | -35.48500M | -44.05200M | -42.70100M | -20.65200M |
| Extraordinary items | - | - | - | - | 0.90M |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 9.72M | 10.56M | -7.91400M | 2.60M | 9.80M |
| Total revenue | 1045.47M | 1010.63M | 862.46M | 955.10M | 859.63M |
| Total operating expenses | 501.19M | 458.32M | 414.29M | 445.60M | 397.81M |
| Cost of revenue | 474.23M | 442.60M | 402.16M | 430.38M | 390.52M |
| Total other income expense net | -140.91600M | 35.26M | 28.57M | 29.62M | -20.65200M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -80.58200M | 62.54M | 9.52M | 28.62M | 40.85M |
| Net income applicable to common shares | -80.58200M | 62.54M | 9.52M | 28.62M | 40.85M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 2300.02M | 2297.59M | 1766.02M | 1751.67M | 1775.10M |
| Intangible assets | 649.48M | 681.80M | 471.05M | 501.54M | 532.80M |
| Earning assets | - | - | - | - | - |
| Other current assets | 30.75M | 28.62M | 23.75M | 17.28M | 17.79M |
| Total liab | 1465.80M | 1552.05M | 980.58M | 1042.63M | 1064.63M |
| Total stockholder equity | 834.22M | 745.54M | 785.43M | 709.04M | 710.47M |
| Deferred long term liab | - | 66.72M | 68.54M | 57.88M | 74.49M |
| Other current liab | 214.29M | 143.76M | 65.71M | 60.84M | 64.83M |
| Common stock | 0.31M | 0.31M | 0.31M | 0.31M | 0.31M |
| Capital stock | 0.31M | 0.31M | 0.31M | 0.31M | 0.31M |
| Retained earnings | 452.53M | 412.63M | 496.61M | 457.42M | 470.84M |
| Other liab | - | 258.66M | 98.80M | 102.46M | 104.23M |
| Good will | 806.84M | 815.43M | 617.53M | 618.44M | 618.04M |
| Other assets | - | 85.82M | 89.03M | 103.64M | 84.91M |
| Cash | 24.30M | 28.94M | 20.85M | 27.36M | 25.86M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 310.73M | 296.55M | 196.65M | 190.20M | 188.09M |
| Current deferred revenue | -8.21700M | 9.65M | 60.49M | 50.17M | 53.69M |
| Net debt | 966.96M | 1025.88M | 663.81M | 748.50M | 742.95M |
| Short term debt | 8.22M | 69.75M | 12.25M | 25.88M | 13.60M |
| Short long term debt | 0.71M | 69.75M | 12.25M | 18.22M | 13.60M |
| Short long term debt total | 991.25M | 1054.82M | 684.66M | 775.86M | 768.81M |
| Other stockholder equity | 431.55M | 390.46M | 342.72M | 314.99M | 298.59M |
| Property plant equipment | - | 115.61M | 108.86M | 111.41M | 118.88M |
| Total current assets | 615.65M | 581.23M | 460.12M | 416.65M | 397.36M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | -751.68300M | -340.82900M | -410.93900M | -440.37500M |
| Short term investments | - | - | - | - | - |
| Net receivables | 242.28M | 191.34M | 183.88M | 177.15M | 189.10M |
| Long term debt | 973.14M | 985.08M | 672.41M | 734.83M | 755.21M |
| Inventory | 318.32M | 332.32M | 231.64M | 194.87M | 164.62M |
| Accounts payable | 88.22M | 73.39M | 58.20M | 53.31M | 55.97M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -50.17000M | -57.85800M | -54.20300M | -63.68100M | -59.27700M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.31M | 0.31M | 0.31M | 0.31M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | 412.63M | 496.61M | 457.42M | 470.84M |
| Treasury stock | - | -22.77600M | -54.05100M | -67.63900M | -80.73700M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 96.11M | 93.88M | 98.80M | 96.79M | 102.35M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 1684.37M | 1716.37M | 1305.89M | 1335.02M | 1377.73M |
| Capital lease obligations | - | - | - | 22.81M | - |
| Long term debt total | - | 985.08M | 672.41M | 735.22M | 755.21M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | -21.49500M | -249.52900M | -14.86600M | -13.63800M | -387.66200M |
| Change to liabilities | - | 10.80M | 15.27M | -2.97700M | 0.04M |
| Total cashflows from investing activities | - | -249.52900M | -14.86600M | -13.63800M | -387.66200M |
| Net borrowings | - | 340.19M | -83.24300M | -29.40300M | 346.64M |
| Total cash from financing activities | -110.43200M | 225.00M | -101.54800M | -52.05900M | 300.88M |
| Change to operating activities | - | -26.95900M | -11.94700M | -8.80500M | -7.75800M |
| Net income | 64.46M | -80.58200M | 62.54M | 9.52M | 28.62M |
| Change in cash | -4.64600M | 8.10M | -6.50900M | 1.50M | 8.35M |
| Begin period cash flow | 28.94M | 20.85M | 27.36M | 25.86M | 17.51M |
| End period cash flow | 24.30M | 28.94M | 20.85M | 27.36M | 25.86M |
| Total cash from operating activities | 125.35M | 33.37M | 111.77M | 64.53M | 95.13M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 51.40M | 69.52M | 70.74M | 72.62M | 72.32M |
| Other cashflows from investing activities | - | -227.74400M | - | -0.62500M | -367.59600M |
| Dividends paid | 24.50M | 23.96M | 23.26M | 22.82M | 22.60M |
| Change to inventory | 14.07M | -78.56400M | -37.80600M | -30.39700M | -0.11700M |
| Change to account receivables | -47.06800M | -5.20300M | -9.15900M | 13.92M | -13.94300M |
| Sale purchase of stock | - | 2.47M | - | - | 30.57M |
| Other cashflows from financing activities | 2.07M | 1146.94M | 382.12M | 196.01M | 962.63M |
| Change to netincome | - | 130.22M | 20.24M | 55.01M | 6.08M |
| Capital expenditures | 19.03M | 21.79M | 14.87M | 13.01M | 20.07M |
| Change receivables | - | -5.20300M | -9.15900M | - | - |
| Cash flows other operating | - | -17.73500M | -24.00500M | - | 66.51M |
| Exchange rate changes | - | - | -1.86500M | 2.67M | -0.00700M |
| Cash and cash equivalents changes | - | 8.84M | -6.50900M | 1.50M | 8.35M |
| Change in working capital | -39.57900M | -90.69800M | -55.69700M | -29.90300M | -23.64700M |
| Stock based compensation | 24.26M | 21.73M | 16.34M | 13.11M | 11.78M |
| Other non cash items | 24.11M | 119.44M | 14.84M | 13.41M | 12.37M |
| Free cash flow | 106.32M | 11.58M | 96.90M | 51.52M | 75.07M |
Sector: Healthcare Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CNMD CONMED Corporation |
-0.95 2.41% | 38.46 | 17.71 | 27.03 | 1.79 | 2.47 | 2.49 | 11.89 |
| ABT Abbott Laboratories |
-2.1 1.86% | 110.55 | 37.15 | 23.15 | 4.67 | 4.97 | 4.88 | 19.38 |
| SYK Stryker Corporation |
-7.27 1.99% | 358.65 | 44.07 | 24.94 | 5.51 | 6.12 | 6.05 | 25.73 |
| MDT Medtronic PLC |
-1.45 1.59% | 89.89 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| BSX Boston Scientific Corp |
-1.94 2.70% | 69.96 | 68.17 | 24.57 | 5.85 | 4.26 | 6.46 | 26.80 |
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. It markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. The company also provides battery-powered and autoclavable bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under Hall surgical brand name. In addition, it offers general surgery products, including clinical insufflation systems under AirSeal brand; smoke removal devices under Buffalo Filter brand; endomechanical products, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors used in minimally invasive surgeries; and electrosurgical solution comprising monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems and other accessories. Further, the company provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products for the treatment of diseases of the dilatation, hemostasis, biliary, structure management, and infection prevention and patient monitoring, including ECG and EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.
11311 Concept Boulevard, Largo, FL, United States, 33773-4908
| Name | Title | Year Born |
|---|---|---|
| Mr. Curt R. Hartman | Chairman, CEO & Pres | 1964 |
| Mr. Todd W. Garner | Exec. VP & CFO | 1969 |
| Mr. Patrick J. Beyer | Pres of International & Global Orthopedics | 1966 |
| Mr. Stanley W. Peters III | Pres of Advanced Surgical & Advanced Endoscopic Technologies | 1975 |
| Mr. Daniel S. Jonas Esq. | Special Counsel & Corp. Sec. | 1964 |
| Ms. Heather L. Cohen | Exec. VP and Chief HR & Legal Officer | 1973 |
| Mr. Peter K. Shagory | Exec. VP of Strategy & Corp. Devel. | 1969 |
| Mr. John E. Kennedy | Special Advisor | 1958 |
| Ms. Shanna L. Cotti-Osmanski | Exec. VP of Information Technology & CIO | 1977 |
| Mr. David R. Murray | Pres of ConMed Electrosurgery | 1948 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...